APA (7th ed.) Citation

Galasko, D., Farlow, M. R., Lucey, B. P., Honig, L. S., Elbert, D., Bateman, R., . . . Feldman, H. H. (2024). A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease. Alzheimer's Research & Therapy, 16(1), . https://doi.org/10.1186/s13195-024-01490-z

Chicago Style (17th ed.) Citation

Galasko, Douglas, et al. "A Multicenter, Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in Subjects with Early Alzheimer’s Disease." Alzheimer's Research & Therapy 16, no. 1 (2024). https://doi.org/10.1186/s13195-024-01490-z.

MLA (9th ed.) Citation

Galasko, Douglas, et al. "A Multicenter, Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in Subjects with Early Alzheimer’s Disease." Alzheimer's Research & Therapy, vol. 16, no. 1, 2024, https://doi.org/10.1186/s13195-024-01490-z.